China Nifedipine Market Investigation Report 2021-2025

0

Dublin, December 31, 2021 (GLOBE NEWSWIRE) – The “China Nifedipine Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.com offer.

According to the analyst’s market research, the sales value of nifedipine in the Chinese market increased year on year from 2016 to 2019. In 2020, due to the impact of Covid-19 on the set of diagnostic and medical treatment services, the sales value of nifedipine in the Chinese market fell to CNY 730 million, and the CAGR of nifedipine from 2016 to 2020 was 4.42%.

The analyst expects that with the relief of Covid-19, the sales value of nifedipine in the Chinese market will experience restorative growth from 2021 to 2025. In addition, in recent years, nearly 20 million people around the world have died from cardiovascular and cerebrovascular disease caused by hypertension and coronary heart disease every year.

Nifedipine is a dihydropyridine calcium channel blocker, which is mainly used to bind to L-type calcium channels. Nifedipine is mainly used to treat chronic stable angina pectoris, vasospasm (angina pectoris, angina pectoris variant) and essential hypertension. Nifedipine was developed by Bayer AG, and nifedipine from Bayer AG is marketed under the name ADALAT. By 2020, there are several manufacturers in the Chinese nifedipine market, among which Bayer AG has the highest market share by sales value.

It is estimated that 300 million patients live with high blood pressure in China. As the aging of the population in China becomes more and more severe, the number and prevalence of patients is increasing year by year. Therefore, there is an increasing trend in the sales volume of nifedipine for the treatment of angina and hypertension.

At the same time, compared to similar drugs, nifedipine has a longer time of action, fewer doses, more stable blood levels, and fewer toxic and side effects. Based on these advantages, the sales volume and sales value of nifedipine in the Chinese market will continue to grow from 2021 to 2025.

Topics covered:

  • The impact of COVID-19 on the Chinese nifedipine market

  • 2016-2020 Chinese Nifedipine Sales Value

  • Competitive Landscape of the Chinese Nifedipine Market

  • Nifedipine Price in China

  • China Nifedipine Price by Regions and Manufacturers

  • Analysis of Factors Affecting the Development of China Nifedipine Market

  • China Nifedipine Market Outlook 2021-2025

Main topics covered:

1 Relevant concepts of nifedipine
1.1 Indications for nifedipine
1.2 Development of nifedipine in China
1.3 Government approval of nifedipine in China
1.4 The impact of COVID-19 on sales of nifedipine in China

2 China Nifedipine Sales, 2016-2020
2.1 Sales value of nifedipine
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Nifedipine Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Nifedipine Sales by Dosage Form, 2016-2020
2.3.1 Controlled-release tablets
2.3.2 Tablets
2.3.3 Prolonged-release tablets
2.3.4 Soft capsules

3 China Major Manufacturers Analysis of Nifedipine, 2016-2020
3.1 Major Manufacturers of Nifedipine Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Bayer SA
3.2.1 Company profile
3.2.2 Sales of ADALAT (Bayer AG’s Nifedipine) in China
3.3 Shanghai Shyndec Pharmaceutical Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Xinran (Shanghai Shyndec Pharmaceutical Co., Ltd.) Nifedipine in China
3.4 Qingdao Huanghai Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Maikaofen (Qingdao Huanghai Pharmaceutical Co., Ltd.) Nifedipine in China
3.5 Beijing Honglin Pharmaceutical Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Nifuda (Beijing Honglin Pharmaceutical Co., Ltd.) Nifuda in China
3.6 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 Sales of Shansu (Nifedipine from Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.) in China

4 Nifedipine Price for Different Manufacturers in China, 2020-2021
4.1 Bayer SA (ADALAT)
4.2 Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
4.3 Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
4.4 Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
4.5 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd. (Shansu)

5 China Nifedipine Market Outlook, 2021-2025
5.1 Factors Influencing the Development of China Nifedipine Market
5.1.1 The impact of COVID-19 on the Chinese nifedipine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies mentioned

  • Bayer SA (ADALAT)

  • Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)

  • Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)

  • Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)

  • Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd. (Shansu)

For more information on this report, visit https://www.researchandmarkets.com/r/ephsng

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Share.

Comments are closed.